Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma

被引：0
|
作者：
Mollica, Veronica [1 ]
Rizzo, Alessandro [1 ]
Massari, Francesco [1 ]
机构：
[1] Univ Bologna, IRCCS Azienda Osped, Bologna, Italy
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2021年 / 385卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：956 / 957
页数：2
相关论文
共 50 条
  • [1] Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma REPLY
    Bajorin, Dean F.
    Collette, Sandra
    Galsky, Matthew D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (10): : 957 - 957
  • [2] Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
    Bajorin, D. F.
    Witjes, J. A.
    Gschwend, J. E.
    Schenker, M.
    Valderrama, B. P.
    Tomita, Y.
    Bamias, A.
    Lebret, T.
    Shariat, S. F.
    Park, S. H.
    Ye, D.
    Agerbaek, M.
    Enting, D.
    McDermott, R.
    Gajate, P.
    Peer, A.
    Milowsky, M., I
    Nosov, A.
    Antonio Jr, J. N.
    Tupikowski, K.
    Toms, L.
    Fischer, B. S.
    Qureshi, A.
    Collette, S.
    Unsal-Kacmaz, K.
    Broughton, E.
    Zardavas, D.
    Koon, H. B.
    Galsky, M. D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22): : 2102 - 2114
  • [3] Adjuvant immunotherapy in muscle-invasive urothelial carcinoma
    Rizzo, Alessandro
    Mollica, Veronica
    Massari, Francesco
    [J]. LANCET ONCOLOGY, 2021, 22 (06): : E237 - E237
  • [4] Adjuvant immunotherapy in muscle-invasive urothelial carcinoma
    Funada, Satoshi
    Luo, Yan
    [J]. LANCET ONCOLOGY, 2020, 22 (06): : E236 - E236
  • [5] Muscle-invasive Urothelial Carcinoma: Nivolumab versus Placebo
    Lorenz, Judith
    [J]. AKTUELLE UROLOGIE, 2022, 53 (02) : 110 - 110
  • [6] Adjuvant immunotherapy for muscle-invasive urothelial carcinoma of the bladder
    Alevizakos, Michail
    Bellmunt, Joaquim
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (03) : 259 - 267
  • [7] Adjuvant immunotherapy in muscle-invasive urothelial carcinoma reply
    Bellmunt, Joaquim
    [J]. LANCET ONCOLOGY, 2021, 22 (06): : E238 - E238
  • [8] New risk stratification for adjuvant nivolumab for high-risk muscle-invasive urothelial carcinoma
    Saito, Takafumi
    Kanao, Kent
    Matsumoto, Kazuhiro
    Fukumoto, Keishiro
    Igarashi, Daisuke
    Takahashi, Takayuki
    Kaneko, Go
    Shirotake, Suguru
    Nishimoto, Koshiro
    Mizuno, Ryuichi
    Ishida, Masaru
    Hara, Satoshi
    Oya, Mototsugu
    Oyama, Masafumi
    [J]. BJUI COMPASS, 2024, 5 (02): : 281 - 288
  • [9] Muscle-invasive Urothelial Carcinoma: Nivolumab versus Placebo Comment
    Seitz, Anna Katharina
    [J]. AKTUELLE UROLOGIE, 2022, 53 (02) : 112 - +
  • [10] Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma (vol 384, pg 2102, 2021)
    Bajorin, Dean F.
    Witjes, J. Alfred
    Gschwend, Jurgen E.
    Schenker, Michael
    Valderrama, Begona P.
    Tomita, Yoshihiko
    Bamias, Aristotelis
    Lebret, Thierry
    Shariat, Shahrokh F.
    Park, Se Hoon
    Ye, Dingwei
    Agerbaek, Mads
    Enting, Deborah
    McDermott, Ray
    Gajate, Pablo
    Peer, Avivit
    Milowsky, Matthew I.
    Nosov, Alexander
    Neif Antonio, Joao, Jr.
    Tupikowski, Krzysztof
    Toms, Laurence
    Fischer, Bruce S.
    Qureshi, Anila
    Collette, Sandra
    Unsal-Kacmaz, Keziban
    Broughton, Edward
    Zardavas, Dimitrios
    Koon, Henry B.
    Galsky, Matthew D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (09): : 864 - 864
12345